Literature DB >> 16495447

Myelin formation during development of the CNS is delayed in matrix metalloproteinase-9 and -12 null mice.

Peter H Larsen1, Angelika Goncalves DaSilva, Katherine Conant, V Wee Yong.   

Abstract

The matrix metalloproteinases (MMPs) are implicated in several activities within the nervous system. Although many functions of abnormally elevated MMPs are undesirable, the discrete expression of particular MMP members can have beneficial roles. We previously found that MMP-9 expressed locally around a demyelinating lesion of the spinal cord of adult mice facilitated remyelination. In the current study, we have addressed whether and how MMPs might be required for myelin formation in normal ontogeny. Using a probe for multiple MMPs and the developing mouse optic nerve, we found two members, MMP-9 and -12, to be upregulated during the period of myelin formation. These MMPs partake in myelinogenesis because myelination in the corpus callosum of MMP-9 and/or MMP-12 null mice was deficient from postnatal days 7 to 14 compared with that of wild-type mice. The deficient myelination was correlated with fewer mature oligodendrocytes, but similar precursor cell numbers, in MMP null animals compared with wild type. Because an important growth factor for oligodendrocyte maturation is insulin-like growth factor-1 (IGF-1), we addressed whether this was involved in the deficient myelination in MMP null mice. Indeed, the addition of IGF-1 normalized the lack of maturation of oligodendrocytes that occurred in cultures from MMP-12 null mice. Furthermore, we determined that IGF binding protein 6 (IGFBP-6), which sequesters IGF-1, was a substrate for MMP processing. Finally, we found IGFBP-6 levels to remain high in MMP-deficient mice. These results reveal a novel function for MMP-9 and -12 in developmental myelination likely through regulating IGF-1 bioavailability.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16495447      PMCID: PMC6674803          DOI: 10.1523/JNEUROSCI.1880-05.2006

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  48 in total

Review 1.  New functions for the matrix metalloproteinases in cancer progression.

Authors:  Mikala Egeblad; Zena Werb
Journal:  Nat Rev Cancer       Date:  2002-03       Impact factor: 60.716

2.  Purification and analysis of in vivo-differentiated oligodendrocytes expressing the green fluorescent protein.

Authors:  B Fuss; B Mallon; T Phan; C Ohlemeyer; F Kirchhoff; A Nishiyama; W B Macklin
Journal:  Dev Biol       Date:  2000-02-15       Impact factor: 3.582

3.  The chemokine receptor CXCR2 controls positioning of oligodendrocyte precursors in developing spinal cord by arresting their migration.

Authors:  Hui-Hsin Tsai; Emma Frost; Vivien To; Shenandoah Robinson; Charles Ffrench-Constant; Robert Geertman; Richard M Ransohoff; Robert H Miller
Journal:  Cell       Date:  2002-08-09       Impact factor: 41.582

4.  Matrix metalloproteinase-9/gelatinase B is required for process outgrowth by oligodendrocytes.

Authors:  L Y Oh; P H Larsen; C A Krekoski; D R Edwards; F Donovan; Z Werb; V W Yong
Journal:  J Neurosci       Date:  1999-10-01       Impact factor: 6.167

5.  Insulin-like growth factor I protects oligodendrocytes from tumor necrosis factor-alpha-induced injury.

Authors:  P Ye; A J D'Ercole
Journal:  Endocrinology       Date:  1999-07       Impact factor: 4.736

6.  Myelin basic protein isoforms in myelinating and remyelinating rat brain aggregate cultures.

Authors:  G M Kruger; L T Diemel; C A Copelman; M L Cuzner
Journal:  J Neurosci Res       Date:  1999-05-01       Impact factor: 4.164

7.  Negative regulation of central nervous system myelination by polysialylated-neural cell adhesion molecule.

Authors:  P Charles; M P Hernandez; B Stankoff; M S Aigrot; C Colin; G Rougon; B Zalc; C Lubetzki
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

8.  Myelination is altered in insulin-like growth factor-I null mutant mice.

Authors:  Ping Ye; Liqin Li; R Gregg Richards; Richard P DiAugustine; A Joseph D'Ercole
Journal:  J Neurosci       Date:  2002-07-15       Impact factor: 6.167

Review 9.  Metalloproteinases in biology and pathology of the nervous system.

Authors:  V W Yong; C Power; P Forsyth; D R Edwards
Journal:  Nat Rev Neurosci       Date:  2001-07       Impact factor: 34.870

10.  Fibroblast growth factor 2 (FGF2) and FGF receptor expression in an experimental demyelinating disease with extensive remyelination.

Authors:  D J Messersmith; J C Murtie; T Q Le; E E Frost; R C Armstrong
Journal:  J Neurosci Res       Date:  2000-10-15       Impact factor: 4.164

View more
  51 in total

Review 1.  Metzincin proteases and their inhibitors: foes or friends in nervous system physiology?

Authors:  Santiago Rivera; Michel Khrestchatisky; Leszek Kaczmarek; Gary A Rosenberg; Diane M Jaworski
Journal:  J Neurosci       Date:  2010-11-17       Impact factor: 6.167

2.  Matrix metalloproteinase-9 controls proliferation of NG2+ progenitor cells immediately after spinal cord injury.

Authors:  Huaqing Liu; Veronica I Shubayev
Journal:  Exp Neurol       Date:  2011-07-02       Impact factor: 5.330

Review 3.  MMP-12, a Promising Therapeutic Target for Neurological Diseases.

Authors:  Bharath Chelluboina; Koteswara Rao Nalamolu; Jeffrey D Klopfenstein; David M Pinson; David Z Wang; Raghu Vemuganti; Krishna Kumar Veeravalli
Journal:  Mol Neurobiol       Date:  2017-02-02       Impact factor: 5.590

4.  A novel method to establish microglia-free astrocyte cultures: comparison of matrix metalloproteinase expression profiles in pure cultures of astrocytes and microglia.

Authors:  Stephen J Crocker; Ricardo F Frausto; J Lindsay Whitton; Richard Milner
Journal:  Glia       Date:  2008-08-15       Impact factor: 7.452

5.  Matrix metalloproteinase inhibition enhances the rate of nerve regeneration in vivo by promoting dedifferentiation and mitosis of supporting schwann cells.

Authors:  Huaqing Liu; Youngsoon Kim; Sharmila Chattopadhyay; Igor Shubayev; Jennifer Dolkas; Veronica I Shubayev
Journal:  J Neuropathol Exp Neurol       Date:  2010-04       Impact factor: 3.685

Review 6.  Matrix metalloproteinases in the brain and blood-brain barrier: Versatile breakers and makers.

Authors:  Ralf G Rempe; Anika M S Hartz; Björn Bauer
Journal:  J Cereb Blood Flow Metab       Date:  2016-06-20       Impact factor: 6.200

Review 7.  Matrix Metalloproteinases During Axonal Regeneration, a Multifactorial Role from Start to Finish.

Authors:  Lien Andries; Inge Van Hove; Lieve Moons; Lies De Groef
Journal:  Mol Neurobiol       Date:  2016-02-29       Impact factor: 5.590

8.  Transcriptional networks of progressive diabetic peripheral neuropathy in the db/db mouse model of type 2 diabetes: An inflammatory story.

Authors:  Lucy M Hinder; Benjamin J Murdock; Meeyoung Park; Diane E Bender; Phillipe D O'Brien; Amy E Rumora; Junguk Hur; Eva L Feldman
Journal:  Exp Neurol       Date:  2018-03-14       Impact factor: 5.330

9.  MMPs initiate Schwann cell-mediated MBP degradation and mechanical nociception after nerve damage.

Authors:  Hideo Kobayashi; Sharmila Chattopadhyay; Kinshi Kato; Jennifer Dolkas; Shin-Ichi Kikuchi; Robert R Myers; Veronica I Shubayev
Journal:  Mol Cell Neurosci       Date:  2008-09-05       Impact factor: 4.314

Review 10.  Contributions of matrix metalloproteinases to neural plasticity, habituation, associative learning and drug addiction.

Authors:  John W Wright; Joseph W Harding
Journal:  Neural Plast       Date:  2010-02-10       Impact factor: 3.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.